
Reinhard Dummer, MD, of University Hospital Zurich, discusses the results of the phase III COMBI-AD study presented at the 2017 ESMO Congress in patients with stage III BRAF-mutant melanoma.

Your AI-Trained Oncology Knowledge Connection!


Reinhard Dummer, MD, of University Hospital Zurich, discusses the results of the phase III COMBI-AD study presented at the 2017 ESMO Congress in patients with stage III BRAF-mutant melanoma.

Reinhard Dummer, MD, professor, Department of Dermatology, University of Zurich Hospital, discusses driver mutations and next steps in the treatment of patients with melanoma.


Reinhard Dummer, MD, professor, Department of Dermatology, University of Zurich Hospital, discusses the results of the phase III NEMO trial, which compared the efficacy of binimetinib with dacarbazine in patients with NRAS-mutant metastatic melanoma.

Published: August 11th 2016 | Updated:

Published: September 15th 2016 | Updated:

Published: June 7th 2016 | Updated:

Published: September 13th 2017 | Updated: